NovoCure Ltd
NVCR· Nasdaq
NVCRNovoCure Ltd
Filed Feb 27, 2025 · 10-K · 58 days after period end · 0001645113-25-000002
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $161.27M | $133.78M | $128.43M | $133.21M |
| Net Income | -$65.92M | -$47.08M | -$37.30M | -$26.46M |
| EPS Diluted | — | — | -$0.36 | -$0.25 |
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Feb 27, 2025 · 58 d after period end
